These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 38500216)
41. AAV-Mediated Targeting of the Activin A-ACVR1 Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764 [TBL] [Abstract][Full Text] [Related]
42. New Protocol to Optimize iPS Cells for Genome Analysis of Fibrodysplasia Ossificans Progressiva. Matsumoto Y; Ikeya M; Hino K; Horigome K; Fukuta M; Watanabe M; Nagata S; Yamamoto T; Otsuka T; Toguchida J Stem Cells; 2015 Jun; 33(6):1730-42. PubMed ID: 25773749 [TBL] [Abstract][Full Text] [Related]
43. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice. Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847 [TBL] [Abstract][Full Text] [Related]
44. The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A. Szilágyi SS; Burdzinski W; Jatzlau J; Ehrlich M; Knaus P; Henis YI Cells; 2024 Jan; 13(3):. PubMed ID: 38334613 [TBL] [Abstract][Full Text] [Related]
45. Activin A does not drive post-traumatic heterotopic ossification. Hwang C; Pagani CA; Das N; Marini S; Huber AK; Xie L; Jimenez J; Brydges S; Lim WK; Nannuru KC; Murphy AJ; Economides AN; Hatsell SJ; Levi B Bone; 2020 Sep; 138():115473. PubMed ID: 32553795 [TBL] [Abstract][Full Text] [Related]
46. Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification. He K; Jiang H; Li W; Toutounchi S; Huang Y; Wu J; Ma X; Baehr W; Pignolo RJ; Ling K; Zhou X; Wang H; Hu J Sci Transl Med; 2024 Jul; 16(757):eabn3486. PubMed ID: 39047114 [TBL] [Abstract][Full Text] [Related]
47. Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva. Burdick LN; DelVichio AH; Hanson LR; Griffith BB; Bouchard KR; Hunter JW; Goldhamer DJ Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397414 [TBL] [Abstract][Full Text] [Related]
48. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish. Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499 [TBL] [Abstract][Full Text] [Related]
49. BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification. Kan C; Ding N; Yang J; Tan Z; McGuire TL; Lu H; Zhang K; Berger DMP; Kessler JA; Kan L Stem Cell Res Ther; 2019 Jan; 10(1):14. PubMed ID: 30635039 [TBL] [Abstract][Full Text] [Related]
53. Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. Yang YS; Kim JM; Xie J; Chaugule S; Lin C; Ma H; Hsiao E; Hong J; Chun H; Shore EM; Kaplan FS; Gao G; Shim JH Nat Commun; 2022 Oct; 13(1):6175. PubMed ID: 36258013 [TBL] [Abstract][Full Text] [Related]
54. Fibrodysplasia ossificans progressiva. Kaplan FS; Le Merrer M; Glaser DL; Pignolo RJ; Goldsby RE; Kitterman JA; Groppe J; Shore EM Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):191-205. PubMed ID: 18328989 [TBL] [Abstract][Full Text] [Related]
55. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014 [TBL] [Abstract][Full Text] [Related]
56. Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs. Maekawa H; Jin Y; Nishio M; Kawai S; Nagata S; Kamakura T; Yoshitomi H; Niwa A; Saito MK; Matsuda S; Toguchida J Orphanet J Rare Dis; 2022 Sep; 17(1):364. PubMed ID: 36131296 [TBL] [Abstract][Full Text] [Related]
57. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088 [TBL] [Abstract][Full Text] [Related]
58. Patients with ACVR1 Kou S; De Cunto C; Baujat G; Wentworth KL; Grogan DR; Brown MA; Di Rocco M; Keen R; Al Mukaddam M; le Quan Sang KH; Masharani U; Kaplan FS; Pignolo RJ; Hsiao EC Orphanet J Rare Dis; 2020 Jul; 15(1):193. PubMed ID: 32727600 [TBL] [Abstract][Full Text] [Related]
59. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1. Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272 [TBL] [Abstract][Full Text] [Related]
60. Pay Attention to the Osteochondromas in Fibrodysplasia Ossificans Progressiva. Li L; Lu M; He X; Zou C; Zheng C; Wang Y; Tang F; Luo Y; Zhou Y; Min L; Tu C Orthop Surg; 2024 Mar; 16(3):781-787. PubMed ID: 38185793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]